Spurring new research for neglected diseases

Health Affairs

Volumn 28, Issue 6, 2009, Pages 1750-1759

  Anderson, Gerard F ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL RESEARCH; CONFERENCE PAPER; DRUG COST; DRUG INDUSTRY; HEALTH CARE COST; HUMAN; LOWEST INCOME GROUP; MEDICAL RESEARCH; NONHUMAN; TAX; TROPICAL DISEASE; UNITED STATES;

BIOTECHNOLOGY; COMMERCE; COMMUNICABLE DISEASE CONTROL; DEVELOPING COUNTRIES; DRUG EVALUATION, PRECLINICAL; DRUG INDUSTRY; HUMANS; NEGLECTED DISEASES; RESEARCH DESIGN; RESEARCH SUPPORT AS TOPIC; TAX EXEMPTION;

EID: 77952112357     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.28.6.1750     Document Type: Conference Paper

References (24)

1. Musgrove P, Hotez PJ. Turning neglected tropical diseases into forgotten maladies. Health Aff (Millwood). 2009;28(6):1691-706.
2. Food and Drug Administration Amendments Act of 2008 (PL 100-85) [Internet]. Washington (DC): U.S. Government Printing Office; [cited 2009 Sep 15]. Available from httpy/frwebgate.access.gpo.gov/cgibin/getdoc.cgi?dbname=110- cong-public-laws&docid=f:pub1085.110
3. World Bank. Disease control priorities in developing countries. 2d ed. Washington (DC): World Bank; 2006.
4. Mrazek MF, Mossialos E. Stimulating pharmaceutical research and development for neglected diseases. Health Policy. 2003;64(1):75-88.
5. World Heath Organization. Is there any progress being made? [Internet]. Geneva (Switzerland): WHO; 2009 Mar 25 [cited 2009 Feb 18]. Available from: httpy/www.who.int/neglected-diseases/faq/en/index7 .html
6. Ridley R. Product development public-private partnerships for diseases of poverty. In: Widdus R, White K, editors. Combating diseases associated with poverty. Geneva (Switzerland): Institute on Public-Private Partnerships for Health; 2004.
7. Moran M, Guzman J, Ropars AL, McDonald A, Jameson N, Omune B, et al. Neglected disease research and development: how much are we really spending? PLoS Med. 2009;6(2):e30.
8. Grace C. Developing new technologies to address neglected diseases: the role of product development partnerships and advanced market commitments. London (UK): DFID Health Resource Centre; 2006 Jun.
9. Kremer M. Pharmaceuticals and the developing world. J Econ Persp. 2001;16(4):67-90.
10. Pharmaceutical Research and Manufacturers of America. Pharmaceutical industry profile 2008. Table 6. Washington (DC): PhRMA; 2008 Mar. According to the footnote, "Sales abroad includes sales generated outside the United States by U.S.-owned PhRMA member companies and sales generated abroad by the U.S. divisions of foreign-owned PhRMA member companies. Sales generated abroad by the foreign divisions of foreign owned PhRMA member companies are excluded Domestic sales, however, includes sales generated within the United States by all PhRMA member companies."
11. Nwaka S, Ramirez B, Brun R, Maes L, Douglas F, Ridley R. Advancing drug innovation for neglected diseases-criteria for lead progression. PLoS Negl Trop Dis. 2009;3(8):e440.
12. Levine OS, O'Brien KL, Knoll M, Adegbola RA, Black S, Cherian T, et aL Pneumococcal vaccination in developing countries. Lancet. 2006;367(9526):1880-2.
13. Kesselheim AS. Drug development for neglected diseases - the trouble with FDA review vouchers. N Engl J Med. 2008;359(19)0981-3.
14. Sloan F, Hsieh CR. Effects of incentives on pharmaceutical innovation. Mimeo. 2006 Jul 27. p. 14.
15. Congressional Office of Technology Assessment. The effectiveness of research and experimentation tax credits. Washington (DC): OTA; 1995 Sep.
16. U.S. Government Accountability Office. Tax policy and administration: review of studies of the effectiveness of the research tax credit. Washington (DC): GAO: 1996 May.
17. Most profitable pharmaceutical and biotech firms pay at a 35 percent tax rate. The addition of a 50 percent tax credit would provide an expenditure recovery of 85 percent.
18. Institute of Medicine. The U.S. commitment to global health: recommendations for the new administration. Washington (DC): IOM; 2009.
19. Congress has a history of providing tax credits for R&D for a limited period of time and then assessing the value of the tax credit. See, for example, Note 16.
20. Haffner M. Orphan drug development - international program and study design issues. Drug Inform J. 1998;32(11):93-9.
21. Haffner ME. Adopting orphan drugs - two dozen years of treating rare diseases. N Engl J Med. 2006;354 (5):445-7.
22. Shulman SR, Manocchia M. The U.S. orphan drug programme, 1983-1995. PharmacoEconomics. 1997;12 (3):312-26.
23. Office of Inspector GeneraL The Orphan Drug Act: implementation and impact. Washington (DC): OIG; 2001 May.
24. Trouiller P, Olliaro P, Torreele E, Orbinski J, Laing R, Ford N. Drug development for neglected disease: a deficient market and a public-health failure. Lancet. 2002;359(9324):2188-94.